BeiGene
BGNE
#926
Rank
HK$165.99 B
Marketcap
HK$1,483
Share price
-2.08%
Change (1 day)
2.95%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Operating Margin for BeiGene (BGNE)

Operating Margin as of November 2024 (TTM): -28.62%

According to BeiGene 's latest financial reports and stock price the company's current Operating Margin is -28.62%. At the end of 2023 the company had an Operating Margin of -33.59%.

Operating Margin history for BeiGene from 2015 to 2024

Operating Margin at the end of each year

Year Operating Margin Change
2023-33.59%-75.75%
2022-138.50%13.25%
2021-122.30%-76.66%
2020-523.90%137.75%
2019-220.35%-36.68%
2018-348.01%811.02%
2017-38.20%-99.66%
2016-11,136.73%1619.4%
2015-647.71%355.24%
2014-142.28%100.93%
2013-70.81%

Operating Margin for similar companies or competitors

Company Operating Margin Operating Margin differencediff. Country
-8,391.15% 29,219.18%๐Ÿ‡บ๐Ÿ‡ธ USA
-34.14% 19.29%๐Ÿ‡บ๐Ÿ‡ธ USA

What is a company's Operating Margin?

The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.